Kiran Mazumdar Shaw, Executive Chairperson of Biocon Limited, Bengaluru, announced Monday that it has received the Drugs Controller General of India’s approval to market Itolizumab Injection 25mg/5mL solution for emergency use in India for the treatment of cytokine release syndrome in moderate to severe ARDS patients due to COVID-19. Biocon has repurposed Itolizumab, an anti-CD6 IgG1 monoclonal antibody launched in …
